Overall Q2-2017 volume increased 7 percent over the same quarter last year.
We anticipate that third quarter procedures will be reduced, but missed procedures will be scheduled in the fourth quarter.
One surgeon described using a cheap, long-acting Kenalog slurry pellet for DME, RVO, and uveitis.
Scott Gottlieb, MD, told a conference of regulators that the US is on an “unsustainable path.”
The Saint Regis Mohawk Tribe has sovereign immunity from patent challenges.
The company’s review of Alcon and a decision on its fate will be wrapped up before Jimenez leaves.
The Swiss company said results from its second Phase III trial will be available in November.
Another planned expansion would enable the firm’s California plant to produce 100 thousand units a year.
Its gene therapy for retinal disease is under priority review with the FDA.
Systems are outfitted with a MedOne MicroDose injector, controlled by the device’s foot pedal.
Allegro’s DME candidate may work best when used a month after Avastin, study shows.
Presentations included surgeon experience with the IOL-VIP Revolution and the Argus II.
Tests by the ASRS safety committee pointed to one brand as the culprit.
Doctor’s Claw device has been used extensively in past year.
Ophthalmologists Kerry Solomon, MD, and Kyle Smith, MD, founded the company, which provides a cloud-based surgical planning platform for cataract surgery.
The meeting has become the second largest ophthalmic conference in the world.
The segment is expected to generate $3.1 billion in sales in 2017.
The segment is expected to grow 2.3 percent over the next five years.
The Himalayan Cataract Project proposed to develop and deliver sustainable eye care in Nepal, Ethiopia, and Ghana, while Jimmy Carter's Carter Center proposed to eliminate the transmission of river blindness disease in Nigeria.
Rocket CEO Gaurav Shah, MD, will be CEO of the new entity, while Inotek President and CEO David Southwell will join the board.
You are not currently logged in.
©2017 Market Scope
Lost your Password